Does tirzepatide cause low blood sugar? It can, but the answer depends heavily on what else a person is taking. In the Zepbound obesity trial of adults without diabetes, glucose below 54 mg/dL appeared in 0.3% of tirzepatide participants and none on placebo. The risk was higher in people with type 2 diabetes, and higher again when insulin or a sulfonylurea—an older diabetes medicine that makes the pancreas release insulin—was in the picture.
Hypoglycemia is the medical word for low blood sugar. Tirzepatide does not make it impossible, but the trials show why a medication list matters more than the drug name alone.
Why the risk is usually low on tirzepatide alone
Tirzepatide activates GIP and GLP-1 receptors, two gut-hormone signals involved in blood glucose and appetite. It stimulates insulin release in a glucose-dependent way, meaning the effect is stronger when glucose is high and fades as glucose comes down. It also reduces glucagon, a hormone that raises blood sugar. The current Zepbound label describes that mechanism directly.
That built-in brake helps explain the low rate in people without diabetes. It does not protect against every low, and it cannot cancel the effect of another medicine that lowers glucose independently. For the broader adverse-effect picture, tirzepatide side effects covers the stomach, gallbladder and other safety questions.
What the tirzepatide hypoglycemia numbers show
Trials used glucose below 54 mg/dL as their main cutoff for a clinically important low. The populations and background treatments were different, so these percentages should not be blended into one average.
| Trial setting | Low-glucose finding | What it answers |
|---|---|---|
| Zepbound Study 1 / SURMOUNT-1, obesity without diabetes | 0.3% with tirzepatide; 0% with placebo | Low glucose was uncommon, though the label says it was not captured systematically |
| Zepbound Study 2 / SURMOUNT-2, obesity with type 2 diabetes | 4.2% with tirzepatide; 1.3% with placebo | Diabetes and its treatment change the baseline risk |
| SURPASS-4, tirzepatide compared with insulin glargine | 6%–9% with tirzepatide; 19% with glargine | The trial reported fewer lows with tirzepatide than with the insulin comparator |
| SURPASS-5, tirzepatide added to insulin glargine | 14.2%–19.3% with tirzepatide; 12.5% with placebo | Adding tirzepatide to basal insulin is a different risk setting |
SURMOUNT-1 enrolled 2,539 adults without diabetes for 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022). In SURPASS-4, the low-glucose rate was 1%–3% with tirzepatide versus 16% with insulin glargine among participants who were not taking a sulfonylurea (Del Prato et al., The Lancet, 2021). That detail makes the interaction visible.
SURPASS-5 asked a separate question: what happens when tirzepatide is added to long-acting background insulin. Low glucose occurred in 14.2%–19.3% of tirzepatide groups and 12.5% of the placebo group; three severe episodes occurred, all in tirzepatide groups (Dahl et al., JAMA, 2022). These are trial rates, not a personal forecast.
When does tirzepatide cause low blood sugar more often?
The clearest answer is when another glucose-lowering medicine is involved. Insulin lowers glucose directly. Sulfonylureas can keep prompting insulin release even as glucose falls. The Zepbound label therefore warns about using tirzepatide with either class and leaves any medication adjustment to the prescriber.
As of September 18, 2026, the day this article was written, the Zepbound label is marked Revised: 8/2026. The same label sizes the sulfonylurea effect in SURMOUNT-2: low glucose occurred in 10.3% of tirzepatide participants who were also taking an insulin secretagogue such as a sulfonylurea, versus 2.1% of those who were not.
The separate guide to tirzepatide for type 2 diabetes explains where it fits in a wider diabetes plan.
What low blood sugar can feel like
The label lists dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, a fast heartbeat, anxiety or irritability, hunger, weakness and feeling jittery. Those symptoms can overlap with dehydration, fatigue or anxiety, so a symptom by itself does not prove that glucose is low.
Sudden weakness with sweating or confusion deserves more attention than ordinary low energy. Tirzepatide tiredness explains that distinction. The label tells people using insulin or a sulfonylurea to report signs or symptoms of hypoglycemia to their healthcare provider. The site's side-effect reporting guide explains how a report reaches the prescriber, pharmacy and FDA.
Is semaglutide different?
Not in a way that makes the combination question disappear. Semaglutide also has a glucose-dependent insulin effect. In SURPASS-2, glucose below 54 mg/dL was reported in 0.6%, 0.2% and 1.7% of the three tirzepatide groups, versus 0.4% with semaglutide 1 mg (Frías et al., New England Journal of Medicine, 2021). The rates were low in that metformin-only setting; the trial was not a comparison in people also taking insulin or a sulfonylurea.
What a prescription review changes
A useful review starts with the complete medication list, prior low-glucose episodes and current glucose patterns. It also separates a true measured low from nausea, dehydration or fatigue that only feels similar. The prescriber sets the dose and decides whether any other diabetes medicine needs adjustment; trial schedules are not personal instructions.
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The trial numbers above come from branded tirzepatide and cannot establish a formulation-specific rate for a compounded preparation. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
